690265-92-0

Upstream product

• 7223-42-9 1-(prop-2-yn-1-yl)pyrrolidine 
• 589-87-7 1,4-bromoiodobenzene 
• 27793-68-6 decahydro-2,6-naphthalenedione monoethylene ketal 
• 352-34-1 4-fluoro-1-iodobenzene 
• 529-28-2 4-iodoanisol 
• 624-31-7 4-tolyl iodide 
• 696-62-8 para-iodoanisole 
• 231295-19-5 6-chloro-N-methoxy-N-methyl-1H-indole-2-carboxamide 
• 147223-00-5 2,3-Difluoro-4-n-nonoxyphenylboronic acid 
• 50-00-0 formaldehyd 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 16596-41-1 N-aminopyrrolidine 
• 123-75-1 pyrrolidine 
• 75-09-2 dichloromethane 

Downstream Products

• 690265-93-1 1-[3-(4-iodo-phenyl)-prop-2-inyl]-pyrrolidine 

Relevant academic research and scientific papers

Synthesis of 6-Bromo-3a,4-dihydrobenzo[f]isoindolinium Bromides and Their Aqueous-Alkaline Cleavage

Cyclization of allyl[3-(4-bromophenyl)prop-2-ynyl]ammonium bromides under basic catalysis conditions, unlike their propargyl analogs, occurs under heating of the reaction mixture at 90–92°C. Cyclization, which is the main reaction route, is accompanied by

Recyclable Cu/C3N4 composite catalyzed AHA/A3 coupling reactions for the synthesis of propargylamines

The heterogeneous Cu/C3N4 catalyst was found to be efficient for the synthesis of propargylamines using a three-component coupling reaction of alkynes, CH2Cl2 and amines (AHA) without additional base. Moreover,

Simplifying the conductance profiles of molecular junctions: The use of the trimethylsilylethynyl moiety as a molecule-gold contact

Conductance across a metal|molecule|metal junction is strongly influenced by the molecule-substrate contacts, and for a given molecular structure, multiple conductance values are frequently observed and ascribed to distinct binding modes of the contact at each of the molecular termini. Conjugated molecules containing a trimethylsilylethynyl terminus, -C≡CSiMe 3 give exclusively a single conductance value in I(s) measurements on gold substrates, the value of which is similar to that observed for the same molecular backbone with thiol and amine based contacting groups when bound to under-coordinated surface sites.

One-point binding ligands for asymmetric gold catalysis: Phosphoramidites with a TADDOL-related but acyclic backbone

Readily available phosphoramidites incorporating TADDOL-related diols with an acyclic backbone turned out to be excellent ligands for asymmetric gold catalysis, allowing a number of mechanistically different transformations to be performed with good to outstanding enantioselectivities. This includes [2 + 2] and [4 + 2] cycloadditions of ene-allenes, cycloisomerizations of enynes, hydroarylation reactions with formation of indolines, as well as intramolecular hydroaminations and hydroalkoxylations of allenes. Their preparative relevance is underscored by an application to an efficient synthesis of the antidepressive drug candidate (-)-GSK 1360707. The distinctive design element of the new ligands is their acyclic dimethyl ether backbone in lieu of the (isopropylidene) acetal moiety characteristic for traditional TADDOLs. Crystallographic data in combination with computational studies allow the efficiency of the gold complexes endowed with such one-point binding ligands to be rationalized.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.